# Study to Evaluate the Efficacy and Safety of GSK239512 in Schizophrenia

> **NCT01009060** · PHASE2 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 50 (actual)

## Conditions studied

- Schizophrenia

## Interventions

- **DRUG:** GSK239512
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01009060
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-12-01
- **Primary completion:** 2011-08-10
- **Final completion:** 2011-08-10
- **Target enrollment:** 50 (ACTUAL)
- **Last updated:** 2017-11-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01009060

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01009060, "Study to Evaluate the Efficacy and Safety of GSK239512 in Schizophrenia". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT01009060. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*